Compare PZZA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | EVO |
|---|---|---|
| Founded | 1984 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 994.5M |
| IPO Year | 1995 | N/A |
| Metric | PZZA | EVO |
|---|---|---|
| Price | $36.42 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $45.00 | $7.00 |
| AVG Volume (30 Days) | ★ 1.0M | 29.4K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,068,421,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | $172.24 | ★ N/A |
| Revenue Growth | ★ 14.07 | N/A |
| 52 Week Low | $30.16 | $2.31 |
| 52 Week High | $55.74 | $4.42 |
| Indicator | PZZA | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 60.07 | 48.27 |
| Support Level | $35.50 | $2.60 |
| Resistance Level | $38.22 | $3.82 |
| Average True Range (ATR) | 1.53 | 0.07 |
| MACD | 0.43 | 0.00 |
| Stochastic Oscillator | 75.66 | 66.07 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.